XBIO
$3.26+0.23 (+7.59%)
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by...
Recent News
Xenetic Biosciences: Q4 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Thursday reported a loss of $579,000 in its fourth quarter.
Xenetic Biosciences: Q3 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Wednesday reported a loss of $510,000 in its third quarter.
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences: Q2 Earnings Snapshot
FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Tuesday reported a loss of $689,000 in its second quarter.